Objective-PI3Kα (phosphoinositide 3-kinase alpha) is a therapeutic target in oncology, but its role in platelets and thrombosis remains ill characterized. In this study, we have analyzed the role of PI3Kα in vitro, ex vivo, and in vivo in 2 models of arterial thrombosis. Approach and Results-Using mice selectively deficient in p110α in the megakaryocyte lineage and isoform-selective inhibitors, we confirm that PI3Kα is not mandatory but participates to thrombus growth over a collagen matrix at arterial shear rate. Our data uncover a role for PI3Kα in low-level activation of the GP (glycoprotein) VI-collagen receptor by contributing to ADP secretion and in turn full activation of PI3Kβ and Akt/PKB (protein kinase B). This effect was no longer observed at high level of GP VI agonist concentration. Our study also reveals that over a vWF (von Willebrand factor) matrix, PI3Kα regulates platelet stationary adhesion contacts under arterial flow through its involvement in the outside-in signaling of vWF-engaged α IIb β 3 integrin. In vivo, absence or inhibition of PI3Kα resulted in a modest but significant decrease in thrombus size after superficial injuries of mouse mesenteric arteries and an increased time to arterial occlusion after carotid lesion, without modification in the tail bleeding time.
P latelet adhesion and aggregation at sites of vascular injury are essential for normal hemostasis. However, in diseased vessels, platelet accumulation after erosion or rupture of an atherosclerotic plaque can cause occlusive thrombosis leading to ischemic diseases-a major cause of death and disability worldwide. vWF (von Willebrand factor) plays a key role in hemostasis by promoting adhesion and spreading of platelets on exposed subendothelial matrix proteins after arterial injury. Under conditions of rapid blood flow, the GP (glycoprotein) Ib/ IX/V mediates the initial platelet recruitment through its binding to vWF exposed in the subendothelium. 1 Interaction of GP Ib/IX/V with vWF not only mediates platelet rolling and transient adhesion but also initiates a signaling cascade leading to platelet integrin α IIb β 3 (glycoprotein IIb/IIIa) activation (insideout signaling). Under its high-affinity state, α IIb β 3 can interact with fibrinogen but also with the RGD (Arg-Gly-Asp) sequence of the carboxyl-terminal region of vWF, contributing to stable adhesion contact of platelets to vWF under flow conditions. Platelets also interact with collagen through GP VI and α2β 1 leading to strong platelet activation, spreading, and secretion, and in turn thrombus formation. The molecular mechanisms linking GP Ib/vWF interaction to platelet activation remain incompletely characterized although several signaling proteins have been implicated, including PI3Ks (phosphoinositide 3-kinases). 1 During the last decade, class I PI3Ks have been the subject of intense research in several cells types, including platelets. 2, 3 Class I PI3Ks (PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ) are important signaling enzymes producing the lipid second messenger phosphatidylinositol (3, 4, 5) trisphosphate (PtdIns(3,4,5)P 3 ), which, through binding to proteins, organizes functional signal transduction modules. 4 All class I PI3Ks are expressed in platelets. PI3Kδ has modest role in platelets, PI3Kγ is mainly implicated downstream of the ADP receptor P2Y 12 , and PI3Kβ has a major role in platelet signaling. Using pharmacological inhibitors and genetic approaches, we and others have demonstrated that PI3Kβ acts downstream of most platelet receptors and integrins [5] [6] [7] [8] [9] and is critical to maintain the integrity of the thrombus at high shear rate in contrast to PI3Kα. 3, 10 The absence of PI3Kβ cannot be compensated by PI3Kα, suggesting complementary actions for these 2 PI3Ks during platelet activation.
PI3Kα has been involved in IGF-1 (insulin-like growth factor-1)-mediated potentiation of platelet function. 11, 12 Moreover, using pharmacological inhibitors, it has been suggested that PI3Kα and PI3Kβ are both required for full platelet activation by collagen. 8, 9, 13 Although Gilio et al 8 could not distinguish differences in the degree of involvement of PI3Kα and PI3Kβ isoforms in platelet activation by GP VI agonist, Kim et al 9 showed a smaller implication of PI3Kα in GP VI-mediated platelet responses. To precise the role of platelet PI3Kα in hemostasis and thrombosis, we performed a comprehensive study using both, a mouse model in which p110α is selectively inactivated in megakaryocyte lineage 10 and 2 selective inhibitors, A66 and INK1117 (or MLN1117), 14, 15 the latter being in a phase I clinical trial for oncology indications. 16 Our data uncover a role for PI3Kα in low level of GP VI activation by contributing to ADP secretion and in turn full PI3Kβ and Akt/PKB (protein kinase B) activation. This specific effect was no longer observed at high level of GP VI agonist concentration. Our study also reveals that PI3Kα is implicated in the control of platelet stationary adhesion contact over vWF under shear by acting downstream of vWFengaged α IIb β 3 in both, mouse and human. As a consequence, absence or inhibition of PI3Kα in platelets decreased arterial thrombus formation in 2 models of arterial thrombosis in mouse, without modification of the tail bleeding time.
Materials and Methods
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Reagents and Antibodies
Collagen reagent HORM (equine) suspension was purchased from Takeda. DIOC 6 was purchased from Life Technologies. Antibody against p-Akt was purchased from Cell Signaling and Akt from SigmaAldrich. Antibody against vWF was purchased from Dako. The selective PI3Kα inhibitor INK1117 was from Takeda Pharmaceuticals USA, Inc, and A66 was from Selleckchem. Ristocetin was from Stago, and Integrilin was provided by Glaxo Polyethylen glycol-400 grade was from Fisher Scientific UK, Ltd. Serotonin ELISA test was from IBL International. CRP (collagen-related peptide) was from Prof Richard Farndale's laboratory (Cambridge, United Kingdom).
Botrocetin was from Dr. Pierre H. Mangin's laboratory (Strasbourg, France). Wilfactin was purchased from LFB Biomedicaments (France). Murine vWF was from Cécile V. Denis (Paris, France). All other reagents were purchased from Sigma-Aldrich.
Mice
All animal procedures were in accordance with the guidelines of the Ethics Committee on Animal Experimentation and with the French Ministry of Agriculture license (http://anexplo.genotoul.fr). PF4-cre/p110α flox/flox mice (83 males and females) and their p110α flox/flox WT (wild type; 77 males and females) littermates were generated as described previously 10 and are further referred to as p110α null or WT. These animals (C57Bl/6J genetic background; 10 backcrosses) showed normal platelet size and count. Males and females were indifferently used because preliminary analysis revealed no differences between control males and females in the parameters measured in this study.
Preparation of Washed Mouse Platelets and In Vitro Aggregation Studies
Preparation of washed mouse platelets and in vitro aggregation studies are described in Methods in the online-only Data Supplement.
Preparation of Washed Human Platelets
Blood from healthy donors was purchased from the Etablissement Français du Sang (Toulouse) and immediately processed for experiments. Blood was collected into ACD (acid-citrate-dextrose) anticoagulant, and platelets were isolated by successive centrifugation steps essentially as described previously.
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Flow Assays on Collagen, vWF, or Fibrinogen
Flow assays on collagen, vWF, or fibrinogen are described in Methods in the online-only Data Supplement. Briefly, mouse or human blood was drawn into heparin sodium (10 IU/mL). When indicated, human blood was incubated at 37°C with INK1117 (1 µmol/L) or A66 (1 µmol/L) during 10 minutes. Labeled blood was then perfused through a microcapillary for the indicated time at a wall shear rate of 250, 1500, or 4000 s −1 according to the matrix. Platelet adhesion and thrombus formation were visualized with a 40× oil immersion objective.
Serotonin Secretion
Serotonin content was measured using IBL Serotonin ELISA test (RE59121, IBL) according to manufacturer instructions.
Static Adhesion Assay
Static adhesion assay is described in Methods in the online-only Data Supplement. Briefly, glass coverslips were coated with murine vWF. 18 Washed mouse platelet suspensions (10 6 platelets) were preincubated or not with Integrilin and botrocetin (2 µg/mL) for 10 minutes at 37°C and allowed to adhere to vWF surface. For experiment with ristocetin, human platelets were preincubated with ristocetin and when indicated, with the selective PI3Kα inhibitors INK1117 (0.5 µmol/L) or A66 (1 µmol/L) for 10 minutes at 37°C and allowed to adhere to vWF surface (Wilfactin).
Laser-Induced Vessel Wall Injury
Laser-induced vessel wall injury is described in Methods in the online-only Data Supplement.
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Mouse Treatment With INK1117
INK1117 was resuspended in a solution of 5% 1-methyl-2-pyrrolidinone and 95% Polyethylen glycol-400 grade at the concentration of 12 mg/mL. Mice (8- 
Tail Bleeding Time
Tail bleeding time is described in Methods in the online-only Data Supplement.
FeCl 3 -Induced Carotid Artery Thrombosis
FeCl 3 -induced carotid artery thrombosis is described in Methods in the online-only Data Supplement.
Statistical Analysis
Data are expressed as mean±SEM. Data were analyzed first by Shapiro-Wilk test and D'Agostino-Pearson test to confirm the normal distribution. Significance of differences was determined using 2-tailed Student t test, 1-way ANOVA or 2-way ANOVA, and a Bonferroni post hoc analysis. P<0.05 was considered statistically significant. All statistical analyses were performed using GraphPad Prism 6 software.
Results
PI3Kα Contributes to Thrombus Growth Over Collagen Under Shear Conditions
To establish the role of platelet p110α in platelet function in vitro and in vivo, we used our PF4-Cre/p110α flox/flox mouse model in which p110α is selectively deficient in the megakaryocyte lineage (hereafter called p110α null ). The specific deletion of p110α in platelets had no effect on the expression of the other platelet class I PI3K isoforms or surface GPs GP Ib, GP IIb (αIIb), and GP VI. 10 We first investigated platelet adhesion and thrombus formation on fibrillar type I collagen matrix using a microfluidic system under normal and pathological arterial blood flow. The surface covered by platelets and the thrombus volume was monitored by video microscopy during perfusion of heparinized whole blood from WT or p110α null platelet mice. After 2 minutes of flow at an arterial shear rate of 1500 s −1 , WT platelets formed stable thrombi, whereas the surface covered by p110α null platelets and the thrombus volume was significantly reduced ( Figure 1A ). At longer time of perfusion, these differences were reduced and even undetectable after 4 minutes of flow when the thrombi size reached a plateau ( Figure 1A ). In an another set of experiments, the thrombi formed at a shear rate of 1500 s −1 during 90 s were then submitted to a pathological shear rate of 4000 s −1 ( Figure 1B) . A significant difference was still observed after 30 s of flow but then tended to be reduced and was no longer significant ( Figure 1B ). Of note, under this high shear condition, the stability of the thrombi was comparable in WT and p110α null platelet mice. The specific role of PI3Kα lipid kinase activity in thrombus growth was confirmed in similar experiments using heparinized human whole blood treated with the selective PI3Kα inhibitors A66 (1 µM) or INK1117 (1 µM) 14, 15 ( Figure 1C ). The 2 PI3Kα selective inhibitors reproduced the effect observed using blood from p110α null mice. These results indicate that PI3Kα was not mandatory but significantly contributed to thrombus growth at physiological or pathological shear rate over a collagen matrix, and this effect was because of the catalytic activity of PI3Kα.
PI3Kα Is Involved in Aggregation and Akt Activation After Engagement of GP VI by Low Agonist Concentrations
Washed platelets were then stimulated with different agonists triggering either GPCRs (G-protein-coupled receptors; including TXA2 [thromboxane A2] analogue [U46119], thrombin, and ADP) or the collagen receptor GP VI, which uses the ITAM (immunoreceptor tyrosine-based activation motif) of the FcRγ (Fc receptor γ-chain) to stimulate platelets via tyrosine kinases, after addition of CRP or collagen. A decreased aggregation response to low concentrations of CRP or collagen was observed in p110α null platelets ( Figure 2 ). However, increasing the concentrations of GP VI agonists restored a normal aggregation. Platelet aggregation response was normal in response to U46119, thrombin, or ADP, whatever the concentration used ( Figure 2) .
One of the critical downstream effectors of class I PI3K is the Ser/Thr kinase Akt/PKB. 20 As shown in Figure 3Ai , the lack of PI3Kα did not affect Akt phosphorylation after U46619 or thrombin stimulation, even at low doses of agonists. Conversely, p110α
null platelets stimulated by a low dose of CRP (1 µg/mL) showed a strong decrease in Akt phosphorylation. Consistent with the aggregation results, this difference was no longer observed at higher concentrations of CRP (Figure 3Ai ). The phosphorylation of both Ser473 and Thr308 of Akt was reduced at low doses of CRP (1 µg/ mL), and this difference was observed at any time of stimulation tested (Figure 3Aii ). Importantly, invalidation or inhibition of class I PI3Kβ fully inhibited Akt phosphorylation (Figure 3Aiii ), indicating that whereas PI3Kα is important for Akt activation at low level of GP VI activation, PI3Kβ is mandatory. Because platelet activation and Akt phosphorylation by collagen or CRP are dependent on ADP and P2Y 12 , 21, 22 we investigated the potential implication of PI3Kα on platelet secretion. Serotonin release was measured as a read-out of dense granule secretion. Absence or inhibition of PI3Kα reduced platelet dense granule secretion induced by a low dose of CRP ( Figure 3B) . Interestingly, addition of low doses of ADP, unable to induce Akt phosphorylation, could rescue Akt phosphorylation induced by 1 µg/mL CRP in the absence of PI3Kα ( Figure 3C ). As illustrated in Figure 3D , these results revealed a critical role of PI3Kα in initiating the stimulation of platelets exposed to low concentrations of GP VI agonist by contributing to ADP secretion and in turn full activation of PI3Kβ and Akt.
PI3Kα Plays an Important Role in the Stationary Adhesion Contact of Platelets Over vWF Under Flow
We then analyzed by microfluidic and videomicroscopy the role of PI3Kα in the interaction of platelets on immobilized murine vWF during perfusion of heparinized whole blood at high shear rate (4000 s −1 ) to challenge GP Ib/vWF interactions. Platelet translocation and rolling was recorded continuously (Movie 1 in the online-only Data Supplement; Figure 4 ). As expected, WT platelets presented reversible contacts leading to platelet translocation and rolling over vWF. 23 Interestingly, p110α
null platelets translocated and rolled over the vWF matrix but exhibited much shorter stationary adhesion contact compared with WT as shown by the typical tracking profiles ( Figure 4A ). After 2 minutes of flow, quantification indicated that WT platelets spend 76% of their time in arrest versus 36% for p110α null platelets ( Figure 4B ). Consistent with this, real-time analysis revealed that p110α null platelets had a significantly higher velocity compared with WT platelets (12.4 µm/s±1.5 for p110α null versus 6.2 µm/s±1.6 for WT platelets; P≤0.01; n=6; Figure 4C ). This result correlated with a higher distance covered by p110α null platelets between each arrest, compared with WT platelets (14.5 µm±3.2 for p110α null and 5.1 µm±1.1 for WT platelets; P≤0.01; n=6; Figure 4D ).
Moreover, when heparinized human blood, treated with INK1117 (1 µM) for 10 minutes, was perfused over immobilized human vWF at 4000 s −1 for 3 minutes, we observed a significant decrease in platelet stationary adhesion contacts ( Figure I in the online-only Data Supplement).
These data indicated that PI3Kα was either involved in the molecular mechanisms linking vWF-GP Ib/IX/V complex interaction to integrin α IIb β 3 inside-out activation or in the outside-in signaling from this integrin engaged by vWF C4 domain to allow stable platelet adhesion.
To investigate whether PI3Kα is involved in the general α IIb β 3 outside-in signaling, heparinized whole blood from null mice were stimulated with collagen, CRP, U46619, or thrombin, and aggregation was assessed using a Chrono-log dualchannel aggregometer under stirring for 5 min. For ADP, whole blood from WT or p110α null mice was drawn into heparin (5000 IU/mL) and was stimulated with ADP, and aggregation was assessed during 5 min. The profiles shown are representative of 5 independent experiments. Quantifications of the maximum of aggregation at 5 min are shown on (right; mean±SEM; n=5 independent experiments; ***P<0 0.001 and *P<0.05 vs WT according to 2-tailed Student t test). 24 Absence of PI3Kα did not affect stable platelet adhesion to immobilized fibrinogen whatever the shear applied (250 or 1500 s −1 ). Moreover, the spreading of WT or p110α null platelets on a fibrinogen-coated surface in the presence of 0.3 U/mL thrombin in static conditions was comparable between p110α 
PI3Kα Mediates Platelet Spreading on vWF in a α IIb β 3 -Dependent Manner
We next investigated the ability of p110α null platelets to extend filopodia on immobilized murine vWF matrix under static conditions in the presence of botrocetin (2 µg/mL), a component of the Bothrops jararaca venom known to bind to the vWF A1 domain allowing platelet activation through a GP Ib-specific mechanism, independent of α IIb β 3 . 25, 26 To assess a potential role of PI3Kα specifically downstream of GP Ib/IX/V, the interaction of α IIb β 3 with vWF was blocked by Integrilin. As shown in the scanning electron micrographs 
-tailed Student t test). C, ADP addition rescues Akt phosphorylation in p110α
null platelets stimulated by 1 µg/mL CRP. Platelets from WT or p110α null mice were stimulated or not by CRP (1 µg/mL) in the absence or presence of ADP at different concentrations as indicated. Lysates were submitted to immunoblotting with anti-Akt-Ser(P)473 or Akt antibodies (control loading). Quantifications by densitometric analysis of the Western blots are shown (mean±SEM; n=3 independent experiments; ***P<0.001 and **P<0.01 according to 2-way ANOVA test). D, Schematic representation of the role of PI3Kα in platelets stimulated by low doses of GP (glycoprotein) VI agonist. After a weak GP VI activation, PI3Kα contributes to ADP secretion, (1) which, via the β/γ subunits of its P2Y 12 receptor, allows a full activation of PI3Kβ, (2) which has a major role downstream of GP VI. The fact that PI3Kα cannot be replaced by PI3Kβ suggests that, under this condition, these kinases have complementary and nonredundant roles. NS indicates nonsignificant. ( Figure 5A, left) , in the presence of Integrilin, vWF was able to support filopodia formation in WT platelets through a GP Ib-dependent and α IIb β 3 -independent mechanism. Filopodia formation of p110α null platelets (right) was indistinguishable from WT platelets ( Figure 5A ) as confirmed by observation of the actin cytoskeleton by confocal microscopy ( Figure 5B ). This result indicated a normal GP Ib signaling toward filopodia formation in the absence of PI3Kα. Another set of experiments was then designed to investigate the role of PI3Kα in lamellipodia formation on immobilized vWF in the presence of ristocetin, a bacterial glycopeptide that binds to the proline-rich region of the A1 domain in vWF. Of note, ristocetin is not recommended for mouse platelet studies 27 ; therefore, we used human platelets. vWF/ristocetin is known to generate full spreading and robust stress fiber formation through a pathway that is dependent on α IIb β 3 . 25, 26 In absence of ristocetin, human platelets were unable to spread on vWF ( Figure III in the online-only Data Supplement). Forty minutes after addition of untreated washed human platelets on vWF in the presence of ristocetin, we observed an enrichment of cortical F-actin at the cell periphery and stress fibers in the center of spread platelets ( Figure 5C , left). Interestingly, 2 unrelated selective inhibitors of p110α (INK1117 and A66) strongly affected actin reorganization and significantly reduced the mean platelet spreading ( Figure 5C ).
We then investigated WT and p110α null platelet spreading on vWF matrix in the presence of the secondary agonist ADP. After 60 minutes, WT murine platelets spread to some extent, formed lamellae-like structure and some filopodia. This was strongly affected by the absence of PI3Kα as shown by quantification of the platelet area ( Figure 5D ). In both genotypes, spreading was prevented by addition of Integrilin, highlighting the importance of integrin α IIb β 3 outside-in signaling in this process.
Taken together, these results show that PI3Kα is an important component of α IIb β 3 outside-in signaling on immobilized vWF but not on immobilized fibrinogen.
Lack of Platelet PI3Kα Affects Thrombus Formation In Vivo Without Increasing the Bleeding Time
We next evaluated the consequence of the lack of platelet PI3Kα in primary hemostasis and thrombus formation in vivo. The tail bleeding time of the p110α null platelet mice was not significantly different from control mice, and the treatment of WT mice with the PI3Kα inhibitor INK1117 (60 mg/kg bodyweight) had no impact ( Figure 6A ). Moreover, we never observed rebleeding in PI3Kα null platelet mice. These data suggested that primary hemostasis was spared in the absence of platelet PI3Kα activity. We next monitored platelet thrombus formation by intravital microscopy after laser beam-induced local injury of mesenteric arterioles ( Figure 6B ). Two types of lesions can be performed by this approach: a deep injury leading to the formation of a thrombus dependent on vWF and thrombin and a superficial lesion that generates a thrombus largely dependent on collagen and vWF. 19 After deep injury, thrombus formation tended to be slightly reduced in p110α null platelet mice compared with WT mice, but the difference was not significance (Figure 6B, bottom) . In contrast, superficial injury of the mesenteric artery induced the formation of a significantly smaller thrombus in p110α null platelet mice as compared with WT mice (364±66 µm 2 in WT versus 166±43 µm 2 in p110α null platelet mice at 30 s; *P=0.0181; Figure 6B , top). Another model of experimental arterial thrombosis triggered by carotid injury with FeCl 3 was tested. Although WT mice had a mean occlusion time of 7.3±0.3 minutes after injury, among 11 p110α null platelet mice, 9 needed a significantly longer time to occlude (mean occlusion time, 12.8±1.1 minutes), and the 2 other mice did not occlude during the 30 minutes of analysis ( Figure 6C, left) . Similar results were obtained with mice fed with the PI3Kα inhibitor INK1117 (60 mg/kg) and subjected to FeCl 3 lesion 5 hours later ( Figure 6C, right) . These results were consistent with the ex vivo data and demonstrated a contribution of PI3Kα catalytic activity to the mechanisms of thrombus formation after arterial injury in vivo.
Discussion
A nonredundant contribution of PI3Kα and PI3Kβ in GP VI signaling was suggested by studies using a pharmacological inhibitor in vitro. 8, 9 In the current study, we confirm that, besides a major role of PI3Kβ, 5 PI3Kα also contributes to GP VI signaling and propose a mechanistic explanation. Indeed, after activation by low doses of GP VI agonists, PI3Kα participates to secretion and that secreted ADP then allows a full activation of PI3Kβ, which has the major role in producing PtdIns(3,4,5)P 3 downstream of GP VI. 28 Accordingly, addition of low doses of ADP could rescue Akt phosphorylation in PI3Kα-deficient platelets stimulated by low concentration of CRP. Our results also show that PI3Kα was dispensable as soon as the concentrations of GP VI agonists (CRP or collagen) increased. It is noteworthy that although PI3Kβ was mandatory for platelet activation whatever the doses of GP VI agonists used, it was unable to compensate the loss of PI3Kα when GP VI is mildly activated. Consistent with these results, we recently observed that the mass of PtdIns(3,4,5)P 3 produced was weakly (20%) but significantly decreased in Figure 5 Continued. with an average of 50 platelets counted per experiment; 2-tailed Student t test). B, Platelets were stained with FITC-conjugated phalloidin antibody for confocal microscopy imaging, and representative images are shown (scale bar=5 µm; 4 independent experiments). PI3Kα mediates α IIb β 3 -dependent platelet spreading on vWF. C, Washed platelet suspensions from human were incubated with ristocetin, in presence or not of the PI3Kα selective inhibitor INK1117 (0.5 µmol/L) or A66 (1 µmol/L) and adhered to vWF surface for 40 min. Platelets were then stained with FITC-conjugated phalloidin antibody for confocal microscopy imaging. Representative images are shown (scale bar=10 µm; 3 independent experiments). Platelet area was analyzed using ImageJ software (mean±SEM; n=3 independent experiments with an average of 400-500 platelets counted per experiment; ***P<0.001 vs control according to 1-way ANOVA test). D, Washed platelets from WT or p110α null mice were allowed to adhere to a vWF surface for 60 min in the presence of ADP (10 µmol/L) and in the absence or presence of the α IIb β 3 inhibitor Integrilin and stained with FITC-conjugated phalloidin antibody for confocal microscopy imaging. Representative images are shown (scale bar=5 µm; 3 independent experiments). Platelets area was analyzed using ImageJ software (mean±SEM; n=3 independent experiments with an average of 400-500 platelets counted per experiment; ***P<0.001 according to 2-way ANOVA test). NS indicates nonsignificant. Mice lacking PI3K (phosphoinositide 3-kinase)-α have normal bleeding time, form smaller thrombi in vivo after superficial injury, and present a decreased occlusion velocity after FeCl 3 -induced carotid injury. A, Absence (left) or pharmacological inhibition (right) of PI3Kα in platelets has no effect on bleeding time. Tail bleeding time was performed on WT (wild type; n=6), p110α null (n=6) or WT mice treated with vehicle (Ve; n=12) or PI3Kα inhibitor (INK1117; n=14). B, PI3Kα is required for thrombus growth in vivo after superficial laser-induced injury of mesenteric arterioles. Superficial (top) or deep (bottom) laser injuries of mesenteric arterioles were performed in WT (n=10) or p110α null (n=10) mice. Thrombus formation was monitored over time by fluorescence microscopy, and typical profiles are shown for each condition. The mean thrombus area was analyzed at 0.3-s intervals, and the shading over the curve represents the SEM at each time point. Bar graphs represent the area of the thrombus at t=30 s or t=200 s after injury and are expressed as the mean±SEM (*P<0.05). Top, n=19 vessels in 6 WT mice, n=18 vessels in 7 p110α-deficient platelet mice. Bottom, n=4 vessels in 4 WT mice, n=6 vessels in 5 p110α-deficient platelet mice. C, Thrombotic response of mice to ferric chloride injury of the carotid artery. Left, Flow rates were measured in the carotid artery from WT or p110α null mice after exposure to 7% FeCl 3 for 3 min. The experiment was stopped after 30 min. For both genotypes (n=9), the time necessary to form a stable occlusion is shown for each mouse. Right, WT mice were treated with the PI3Kα inhibitor INK1117 (60 mg/kg; n=12) or Ve (n=8) and subjected to FeCl 3 lesion 5 h later. The experiment was stopped after 30 min. For both conditions, the time necessary to form a stable occlusion is shown for each mouse (***P<0.001 and *P<0.05 vs WT or Ve according to 2-tailed Student t test). null platelets stimulated by CRP. 28 The identification of this new regulatory loop ( Figure 3D) shed light on the complementary and nonredundant role of class I PI3Kα and PI3Kβ in platelets. PI3Kα being activated by binding to tyrosine phosphorylated residues and, in contrast to PI3Kβ, being independent of the β/γ subunits of heterotrimeric Gi-proteins, it can be stimulated independently of ADP secretion and P2Y 12 activation. 22 Thus, our data together with those from Hers 11 and Kim et al 12 indicate that PI3Kα is an important lipid kinase in platelet priming or activation by low doses of agonists acting through receptors coupled to tyrosine kinase activation.
Using both p110α null platelet mice and selective inhibitors-treated human or mouse blood, we found that PI3Kα was not mandatory but was significantly implicated in ex vivo thrombus formation on collagen at a physiological arterial shear rate. Indeed, although p110α null platelets formed smaller thrombi during the early phase of blood perfusion this difference was no longer detectable after a prolonged period of flow when the thrombi size reached a plateau. These data are consistent with those from Gilio et al 8 using PIK-75 inhibitor-treated human or mice blood; however, the phenotype observed in their study was much stronger than in our study possibly because of PIK-75 off-target effects. In contrast, Blair et al 29 did not observe thrombus formation defect on collagen in the absence of PI3Kα. This discrepancy could be explained by differences in the experimental conditions, particularly by the presence of calcium chelator because the authors used whole blood anticoagulated with citrate, heparin, and D-phenylalanyl-l-prolyl-l-arginine chloromethyl ketone, whereas we only used heparin.
Of note, as we previously observed in p110α null platelets, 10 PI3Kα inhibitors (INK1117 and A66) did not affect thrombus stability. These data suggest that amplification of signaling loops within the core of the thrombus via low diffusion of released agonists and sustained α IIb β 3 activation 30 is not dependent on PI3Kα. In contrast, PI3Kβ is critical to control thrombus stability at high shear rate 10 because it is an essential component of the outside-in signaling of various integrins, including α IIb β 3 , engaged by fibrinogen and of ITAM signaling. 31 Another important new observation is the involvement of PI3Kα in platelet stationary adhesion contact over vWF surface under shear. The interaction of vWF with GP Ib allows surface translocation (rolling) that continues until platelets become activated. At that point, a second step mediated by α IIb β 3 , not required for the initial attachment, supports stationary adhesion contacts of individual platelets via interaction of α IIb β 3 with the C4 domain of vWF, leading to an outside-in signaling and a subsequent cytoskeleton reorganization. 1, 20 The engagement of α IIb β 3 strengthens the interaction of platelets with the adhesive surface resulting in a marked decrease in velocity and in turn to stationary contact. 23, 32, 33 Several signaling molecules have been implicated downstream of GP Ib/ IX/V, including PI3K. 1 However, the implication of PI3K in GP Ib-dependent α IIb β 3 inside-out 34 or outside-in signaling, 25, 35 or both, is still a matter of debate, and the PI3K isoform(s) involved are unknown. Here, we show that PI3Kα was not required for the GP Ib-dependent platelet translocation and rolling over vWF but was important downstream of integrin 36, 37 Mice in which p110α is selectively deficient in the megakaryocyte lineage had normal platelet count 10 and tail bleeding time, consistent with the fact that platelet rolling on vWF was spared and that they responded normally to TXA2, ADP, thrombin, and high concentration of GP VI agonists. Interestingly, these mice exhibited a significant decrease in arterial thrombus formation in 2 different models of experimental thrombosis. In laser-induced thrombosis in mesenteric arterioles with superficial injury, the thrombus, known to be dependent on GP VI-collagen and GP Ib-vWF interactions, was significantly smaller in the absence of platelet PI3Kα. In response to a deep mesenteric artery lesion, where the thrombus formed is thrombin-dependent, 19 absence of platelet PI3Kα had no significant effect. By comparison with antiplatelet drugs like clopidogrel or α IIb β 3 blockers tested in the same model, 38 our data suggest a weaker impact of PI3Kα inhibition on thrombus formation.
In the model of arterial thrombosis triggered by carotid injury with FeCl 3 , 39 the time from injury to complete occlusion of the artery was significantly prolonged in p110α null platelet mice. This model of thrombosis is known to require thrombin and vWF. These data are consistent with the fact that the interaction of platelets to vWF through integrin α IIb β 3 contributes to thrombus growth. 40, 41 We also used PI3Kα inhibitors in vivo to directly analyze the implication of the lipid kinase activity. As observed in p110α null platelet mice, pharmacological inhibition of p110α with INK1117 had no significant impact on the tail bleeding time and reproduced the defect of thrombus formation after FeCl 3 carotid injury. This is important information because selective inhibitors of PI3Kα, including INK1117, are now in clinical trials in the treatment of cancer with gain-of-function mutations in PIK3CA gene. 16, 42 Our data suggest that PI3Kα inhibitors, on their own, are unlikely to increase the bleeding risk as also observed in mouse treated during 7 days with PIK-75 or with a specific siRNA. 43 Accordingly, a clinical trial with INK1117 did not show particular bleeding. 16 However, associations of these inhibitors with antiplatelet drugs and their use in patients with thrombopenia have not been tested.
In conclusion, using both a genetic approach and pharmacological inhibitors, this study provides new mechanistic insight into the role of PI3Kα in platelet activation and arterial thrombosis.
